HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Builds On Oral Care, Counts E-commerce As Emerging Sector

This article was originally published in The Rose Sheet

Executive Summary

Colgate's oral care business gains market share in the third quarter on new product sales, including Colgate Total Daily Repair and Colgate Optic White High Impact. President and CEO Ian Cook says the firm is not underrepresented in e-commerce and it will build its online sales “thoughtfully.”

You may also be interested in...



Activist Investor 'Buzz' Annoys Colgate CEO As Earnings Sting Shareholders

Colgate CEO Ian Cook says speculation its recent organic sales misses and competitive pressure make it an activist investor target is “noise” and the firm will combat competitive pressure through increased advertising, growing e-commerce and expanding its natural product lines.

Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump

J&J says Tylenol outpaced other analgesics in the first quarter as its OTC franchise grew 1.4% on a reported basis to $1.01 bn. CFO Dominic Caruso said new consumer products will add 2 points of incremental growth to the segment in 2017.

Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump

J&J says Tylenol outpaced other analgesics in the first quarter as its OTC franchise grew 1.4% on a reported basis to $1.01 bn. CFO Dominic Caruso said new consumer products will add 2 points of incremental growth to the segment in 2017.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel